News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
281,308 Results
Type
Article (14888)
Company Profile (298)
Press Release (266117)
Multimedia
Podcasts (75)
Webinars (11)
Section
Business (79877)
Career Advice (161)
Deals (13332)
Drug Delivery (38)
Drug Development (50745)
Employer Resources (31)
FDA (5834)
Job Trends (5171)
News (145162)
Policy (10092)
Tag
Academia (922)
Accelerated approval (19)
Adcomms (14)
Allergies (80)
Alliances (21786)
ALS (124)
Alzheimer's disease (1024)
Antibody-drug conjugate (ADC) (233)
Approvals (6023)
Artificial intelligence (250)
Autoimmune disease (105)
Automation (9)
Bankruptcy (105)
Best Places to Work (4566)
BIOSECURE Act (6)
Biosimilars (98)
Biotechnology (229)
Bladder cancer (100)
Brain cancer (45)
Breast cancer (332)
Cancer (3045)
Cardiovascular disease (233)
Career advice (147)
Career pathing (7)
CAR-T (215)
CDC (5)
Cell therapy (552)
Cervical cancer (14)
Clinical research (43579)
Collaboration (1105)
Company closure (2)
Compensation (569)
Complete response letters (37)
COVID-19 (1123)
CRISPR (84)
C-suite (519)
Cystic fibrosis (111)
Data (4220)
Denatured (13)
Depression (89)
Diabetes (251)
Diagnostics (1376)
Digital health (10)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (182)
Drug pricing (46)
Drug shortages (3)
Duchenne muscular dystrophy (207)
Earnings (31600)
Editorial (23)
Employer branding (4)
Employer resources (29)
Events (51568)
Executive appointments (615)
FDA (7516)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (9)
Frontotemporal dementia (22)
Funding (958)
Gene editing (175)
Generative AI (20)
Gene therapy (474)
GLP-1 (493)
Government (1146)
Grass and pollen (3)
Guidances (163)
Healthcare (6619)
HIV (17)
Huntington's disease (41)
IgA nephropathy (74)
Immunology and inflammation (183)
Immuno-oncology (35)
Indications (55)
Infectious disease (1227)
Inflammatory bowel disease (153)
Inflation Reduction Act (10)
Influenza (37)
Intellectual property (162)
Interviews (18)
IPO (7339)
IRA (12)
Job creations (867)
Job search strategy (129)
JPM (33)
Kidney cancer (9)
Labor market (22)
Layoffs (243)
Leadership (9)
Legal (1400)
Liver cancer (40)
Longevity (9)
Lung cancer (415)
Lymphoma (243)
Machine learning (23)
Management (7)
Manufacturing (362)
MASH (129)
Medical device (2660)
Medtech (2667)
Mergers & acquisitions (6598)
Metabolic disorders (705)
Multiple sclerosis (97)
NASH (13)
Neurodegenerative disease (218)
Neuropsychiatric disorders (65)
Neuroscience (1912)
NextGen: Class of 2026 (2045)
Non-profit (867)
Now hiring (28)
Obesity (317)
Opinion (125)
Ovarian cancer (127)
Pain (94)
Pancreatic cancer (155)
Parkinson's disease (221)
Partnered (12)
Patents (289)
Patient recruitment (308)
Peanut (43)
People (26587)
Pharmaceutical (44)
Pharmacy benefit managers (6)
Phase I (15440)
Phase II (20243)
Phase III (12802)
Pipeline (2995)
Policy (87)
Postmarket research (855)
Preclinical (6531)
Press Release (30)
Prostate cancer (142)
Psychedelics (48)
Radiopharmaceuticals (235)
Rare diseases (612)
Real estate (1448)
Recruiting (12)
Regulatory (9823)
Reports (19)
Research institute (969)
Resumes & cover letters (18)
Rett syndrome (23)
RNA editing (20)
RSV (16)
Schizophrenia (120)
Series A (178)
Series B (131)
Service/supplier (1)
Sickle cell disease (76)
Special edition (18)
Spinal muscular atrophy (118)
Sponsored (15)
Startups (2005)
State (1)
Stomach cancer (5)
Supply chain (32)
Tariffs (17)
The Weekly (61)
Vaccines (330)
Venture capital (64)
Weight loss (168)
Women's health (24)
Worklife (2)
Date
Today (48)
Last 7 days (195)
Last 30 days (1135)
Last 365 days (18045)
2026 (990)
2025 (18098)
2024 (20552)
2023 (22425)
2022 (26910)
2021 (27861)
2020 (23376)
2019 (16241)
2018 (11761)
2017 (13756)
2016 (11860)
2015 (14367)
2014 (10409)
2013 (7493)
2012 (7549)
2011 (7636)
2010 (7449)
Location
Africa (154)
Alabama (63)
Alaska (2)
Arizona (68)
Arkansas (5)
Asia (18230)
Australia (3100)
California (6919)
Canada (1808)
China (751)
Colorado (242)
Connecticut (245)
Delaware (228)
Europe (39109)
Florida (871)
Georgia (206)
Hawaii (2)
Idaho (17)
Illinois (388)
India (33)
Indiana (155)
Iowa (8)
Japan (210)
Kansas (80)
Kentucky (9)
Louisiana (7)
Maine (11)
Maryland (724)
Massachusetts (5476)
Michigan (106)
Minnesota (243)
Mississippi (3)
Missouri (32)
Montana (16)
Nebraska (5)
Nevada (31)
New Hampshire (20)
New Jersey (1614)
New Mexico (13)
New York (1723)
North Carolina (810)
North Dakota (6)
Northern California (3390)
Ohio (176)
Oklahoma (11)
Oregon (24)
Pennsylvania (1251)
Puerto Rico (9)
Rhode Island (25)
South America (212)
South Carolina (9)
Southern California (2733)
Tennessee (39)
Texas (891)
United States (22852)
Utah (94)
Virginia (133)
Washington D.C. (36)
Washington State (575)
West Virginia (1)
Wisconsin (40)
281,308 Results for "celsius therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
AbbVie Acquires Celsius Therapeutics
AbbVie (NYSE: ABBV) announced today the acquisition of Celsius Therapeutics, Inc. (“Celsius”), a privately held biotechnology company pioneering new therapies for patients with inflammatory disease.
June 27, 2024
·
4 min read
Deals
AbbVie Expands Immuno Portfolio With $250M Celsius Buy as Humira Hits Patent Cliff
AbbVie on Thursday announced it has acquired Celsius Therapeutics to expand its immunology portfolio with a first-in-class TREM1 inhibitor CEL383, following other big players looking to cash in on the hot immuno market.
June 28, 2024
·
2 min read
·
Tristan Manalac
Drug Development
Celsius Therapeutics Announces Initiation of Dosing in Phase 1 Clinical Trial of CEL383, an Anti-TREM1 Antibody for the Treatment of Inflammatory Bowel Disease
Celsius Therapeutics today announced the initiation of dosing in the company’s first-in-human Phase 1 clinical trial of CEL383 in healthy volunteers.
August 3, 2023
·
2 min read
Business
Celsius Therapeutics Names Scientific Advisers
Celsius Therapeutics, a biotechnology company pioneering new precision medicines for patients with cancer and autoimmune disease by harnessing the power of single-cell RNA sequencing and human biology at scale, today announced the appointments of six scientific advisers.
September 22, 2022
·
3 min read
Business
Celsius Therapeutics Appoints Sarah Grant, M.D., as Chief Medical Officer
Celsius Therapeutics today announced the appointment of Sarah Grant, M.D., as chief medical officer.
August 25, 2022
·
2 min read
Drug Development
Celsius Therapeutics to Present Preclinical Data on Anti-TREM1 Antibody at 18th Congress of ECCO - Inflammatory Bowel Diseases
Celsius Therapeutics today announced that new data on CEL383, a potential first-in-class anti-TREM1 antibody for the treatment of inflammatory bowel disease (IBD), has been selected for a digital oral presentation at the 18th Congress of ECCO.
February 27, 2023
·
2 min read
Genetown
Celsius Therapeutics Highlights Recent Accomplishments and Key Initiatives for 2022
Celsius Therapeutics provided a summary of recent corporate highlights, including the nomination of its first clinical candidate for inflammatory bowel disease, an additional $83 million in financing and key initiatives for 2022.
March 24, 2022
·
4 min read
Genetown
Celsius Therapeutics to Present Preclinical Data on Anti-TREM1 Antibody for Inflammatory Bowel Disease at 2023 Crohn’s & Colitis Congress
Celsius Therapeutics today announced that new data on CEL383, a potential first-in-class anti-TREM1 antibody for the treatment of inflammatory bowel disease (IBD), has been selected for oral presentation at the 6th Annual Crohn’s & Colitis Congress, taking place January 19-21, 2023, in Denver, Colorado.
January 19, 2023
·
2 min read
Press Releases
Swiss Rockets Group and Alloy Therapeutics Partner to Advance Radioligand Therapeutics in Oncology
January 12, 2026
·
3 min read
Press Releases
Force Therapeutics Celebrates 2025 Research Impact
January 9, 2026
·
2 min read
1 of 28,131
Next
